This is a working overview of thymalfasin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-03 and is reviewed periodically as new material appears.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20 °C or below | Desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity and identity |
| Common synonyms | Thymalfasin, T alpha 1 | Sequence identical to natural fragment |
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Histamine-mediated responses such as increased capillary permeability and vasodilation have been observed following intradermal administration of some opioids. However, nalbuphine does not elicit either a wheal or flare response, suggesting it does not promote histamine release from mast cells.
=== Polysaccharides === Certain compounds found in mushrooms, primarily polysaccharides, can up-regulate the immune system and may have anti-cancer properties. For example, beta-glucans such as lentinan have been shown in laboratory studies to stimulate macrophage, NK cells, T cells and immune system cytokines and have been investigated in clinical trials as immunologic adjuvants.
== Preparation and use == Fruits can be dried whole (e.g., grapes, berries, apricot, plum), in halves, or as slices (e.g., mango, papaya, kiwi). Alternatively, they can be chopped after drying (e.g., dates), made into pastes, or concentrated juices. The residual moisture content can vary from small (3–8%) to substantial (16–18%), depending on the type of fruit. Fruits can also be spread out, dried and cut into strips in its puree form without the addition of sugar or fats with at least 50% moisture content as fruit leather, (see patent listed under the references section) or as a powder by spray or drum drying. They can be freeze dried. Fresh fruit is frozen and placed in a drying chamber under a vacuum. Heat is applied, and water evaporates from the fruit while it is still frozen. The fruit becomes very light and crispy and retains much of its original flavor. Dried fruit is widely used by the confectionery, baking, and sweets industries. Food manufacturing plants use dried fruits in various sauces, soups, marinades, garnishes, puddings, and food for infants and children. As ingredients in prepared food, dried fruit juices, purées, and pastes impart sensory and functional characteristics to recipes:
Sources: en.wikipedia.org
== Environment == Traces of prescription drugs—including antibiotics, anti-convulsants, mood stabilizers and sex hormones—have been detected in drinking water. Pharmaceutically active compounds (PhACs) discarded from human therapy and their metabolites may not be eliminated by sewage treatment plants and have been detected at low concentrations in surface waters downstream from those plants. The continuous discarding of incompletely treated water may interact with other environmental chemicals and lead to uncertain ecological effects. Due to most pharmaceuticals being highly soluble, fish and other aquatic organisms are susceptible to their effects. The long-term effects of pharmaceuticals in the environment may affect survival and reproduction of such organisms. However, levels of medical drug waste in the water is at a low enough level that it is not a direct concern to human health. However, processes, such as biomagnification, are potential human health concerns. On the other hand, there is clear evidence of harm to aquatic animals and fauna. Recent advancements in technology have allowed scientists to detect smaller, trace quantities of pharmaceuticals in the ng/ml range. Despite being found at low concentrations, female hormonal contraceptives may cause feminizing effects on male vertebrate species, such as fish, frogs and crocodiles. The FDA established guidelines in 2007 to inform consumers should dispose of prescription drugs.
== External links == Cancer Research UK: An intelligent knife can tell ovarian cancer and healthy tissue apart. Could it make surgery smarter?[1] "Intelligent knife" tells surgeon if tissue is cancerous by Sam Wong Surgical Knife May Sniff Out Cancer By Tanya Lewis, Staff Writer | October 10, 2013 Heath, Nick, The Intelligent knife that helps surgeons sniff out cancer, European Technology, November 26, 2014, distributed in TechRepublic Daily Digest, TechRepublic.com, November 27, 2014 Jeevan, R; Cromwell, D. A; Trivella, M; Lawrence, G; Kearins, O; Pereira, J; Sheppard, C; Caddy, C. M; Van Der Meulen, J. H. P (2012). "Reoperation rates after breast conserving surgery for breast cancer among women in England: Retrospective study of hospital episode statistics". BMJ. 345 e4505. doi:10.1136/bmj.e4505. PMC 3395735. PMID 22791786. https://web.archive.org/web/20140322224442/http://www.doublexscience.org/iknife-excises-uncertainty-in-tumor-resection/
Solid wastes include whole dead or damaged fish, trimmings, heads, viscera, gills, tails, fins, skin, scales and bones. They also include solid residues left after oil or protein extraction. Depending on their composition and quality, these materials can be processed into fish meal, fish oil and fertilizers, or used to produce biogas through anaerobic digestion. Fish oil recovered from these wastes can also be used to produce biodiesel. Liquid wastes: include bloodwater and brine from drained storage tanks, and water discharges from washing and cleaning. This waste may need holding temporarily, and should be disposed of without damage to the environment. How liquid waste should be disposed from fish processing operations depends on the content levels in the waste of solid and organic matter, as well as nitrogen and phosphorus content, and oil and grease content. It also depends on an assessment of parameters such acidity levels, temperature, odour, and biochemical oxygen demand and chemical oxygen demand. The magnitude of waste management issues depends on how much waste volume there is, the nature of the pollutants it carries, the rate at which it is discharged and the capacity of the receiving environment to assimilate the pollutants. Many countries dispose of such liquid wastes through their municipal sewage systems or directly into a waterway. The receiving waterbody should be able to degrade the organic and inorganic waste components in a way that does not damage the aquatic ecosystem. Treatments can be primary and secondary.
Have a diagnosable opioid use disorder, according to the DSM-5, Be actively addicted to opioids at the time of intake, and Have been addicted to opioids for at least one year before beginning treatment. In addition to these federal criteria, each state may have its own criteria individuals must meet. The US GAO also cited the cost of treatment and lack of health insurance coverage for MAT as barriers for many addicted to opioids. While methadone treatments are covered by Medicaid for low-income individuals, the extent of coverage depends on which state they are in and if the state has opted into Medicaid expansion under the Affordable Care Act. Buprenorphine, on the other hand, is not covered by Medicaid or, often, even by private health insurers. Because buprenorphine must typically be paid for out-of-pocket, lower-income individuals are often priced out of the lower-risk MAT. In some areas this creates major disparities along racial lines with the higher-risk treatment utilized by lower-income individuals - disproportionately represented by people of color - and the lower-risk treatment only accessible to higher-income individuals - disproportionately represented by whites. Other individual-level barriers may include transportation, especially for those who live in rural areas. The nearest Opioid Treatment Program (OTP) could be up to an hour away, and when daily methadone doses are required for treatment, this may interfere with the success of the MAT or the client's compliance in the program.
Sources: en.wikipedia.org
=== Greek philosophy === Aristotle's The Parts of Animals sets out enough details of his views on metabolism for an open flow model to be made. He believed that at each stage of the process, materials from food were transformed, with heat being released as the classical element of fire, and residual materials being excreted as urine, bile, or faeces. Ibn al-Nafis described metabolism in his 1260 AD work titled Al-Risalah al-Kamiliyyah fil Siera al-Nabawiyyah (The Treatise of Kamil on the Prophet's Biography) which included the following phrase "Both the body and its parts are in a continuous state of dissolution and nourishment, so they are inevitably undergoing permanent change."
Use of the opium poppy predates written history. The making and use of opium was known to the ancient Minoans. Its sap was later named opion by the ancient Greeks. The English name is based on the Latin adaptation of the Greek form. Evidence of the early domestication of opium poppy has been discovered through small botanical remains found in regions of the Mediterranean and west of the Rhine River, predating circa 5000 BC. These samples found in various Neolithic sites show the incredibly early cultivation and natural spread of the plant throughout western Europe. Opium was used for treating asthma, stomach illnesses, and bad eyesight. Opium became a major colonial commodity, moving legally and illegally through trade networks on the Indian subcontinent, the Colonial United States, Qing China and others. Members of the East India Company saw the opium trade as an investment opportunity beginning in 1683. In 1773, the Governor of Bengal established a monopoly on the production of Bengal opium, on behalf of the East India Company administration. The cultivation and manufacture of Indian opium was further centralised and controlled through a series of acts issued between 1797 and 1949. East India Company merchants balanced an economic deficit from the importation of Chinese tea by selling Indian opium which was smuggled into China in defiance of Qing government bans. This trade led to the First and Second Opium Wars.
Transgenic mice with a fluorescently tagged UBE3A were used to test the effectiveness of unsilencing the paternal copy. When tested on mice in vivo, topotecan affected the hippocampus, striatum and cerebral cortex but not the cerebellum unless a higher dose was administered (21.6 micrograms/hour for five days). The study suggested that the topoisomerase inhibitors have the potential to produce a normally functioning UBE3A protein. Most symptoms due to Angelman syndrome are traditionally treated by speech therapy, physical therapy and occupational therapy. Anti-seizure medication is often prescribed as seizures are a common symptom of Angelman syndrome. These treatments target only symptoms. This drug has been administered to cancer patients. It was well tolerated when administered to pediatric and adult patients.
Sources: en.wikipedia.org
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.
Mass spectrometry gives the molecular mass, which is compared with the calculated value. Reversed-phase liquid chromatography shows purity and the presence of related impurities. Peptide mapping can verify the amino acid sequence when a higher level of detail is needed.
It reports the tests the supplier performed, which may vary between laboratories and lots. Methods and acceptance criteria are not standardised across suppliers. Buyers often request the actual chromatograms and spectra rather than a summary statement.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.